Ngomhla wama-31 kuMatshi 2026, iZiko loVavanyo lwaMayeza le-China's National Medical Products Administration lizise iindaba ezimnandi: i-GFH375, eyenziwe yiGenFleet Therapeutics, ifakiwe ngokusemthethweni njengoMviwa we-"Breakthrough Therapy" wokunyanga izigulana ezinomhlaza wepancreatic osasazekileyo one-metastatic pancreatic cancer equlethe i-KRAS G12D mutation ezifumene ubuncinane unyango olunye lwangaphambili. Oku kubonisa inyathelo elibalulekileyo eliya phambili kwicandelo lokunyanga ngokuchanekileyo umhlaza wepancreatic.
Ukuba wena okanye umntu omthandayo unengxaki yomhlaza wepancreatic oguqukileyo we-KRAS G12D-mutant, musa ukuphelelwa lithemba. ISebe le-Beijing South Region Oncology Hospital International (400-880-3716) lilandela ngokusondeleyo olu phuhliso lwangoku kwaye linikezela ngeenkonzo zokubonisana zobungcali kunye nokulungelelanisa unyango kwizigulane zamazwe ngamazwe.
**Malunga neGFH375/VS-7375**
I-GFH375 sisithinteli esisebenza ngomlomo, esinamandla, nesikhetha kakhulu i-KRAS G12D (ON/OFF) esincinci esenzelwe ukujolisa ekutshintshiselaneni kwe-GTP/GDP, ngaloo ndlela siphazamisa ukusebenza kwendlela esezantsi kwaye sithintele ngokufanelekileyo ukwanda kweeseli zethumba. Izifundo zangaphambi kweklinikhi zibonise ukuthintelwa okuxhomekeke kwidosi kwiimodeli ezine-KRAS G12D mutations; I-GFH375 ikwabonise umngcipheko ophantsi ongekho kwithagethi ekukhetheni i-kinase kunye novavanyo lokhuseleko.
I-GenFleet ingene kwintsebenziswano yokufumanisa nokuphuhlisa neVerastem Oncology (Nasdaq: VSTM) ukuze iqhubele phambili iinkqubo ezintathu ezintsha ze-oncology ezijolise kumhlaza oqhutywa yi-RAS/MAPK. Le ntsebenziswano inika iVerastem ukhetho olukhethekileyo lokufumana ilayisenisi yekhompawundi nganye kwezi zintathu emva kokugqitywa ngempumelelo kweziganeko ezibalulekileyo kuvavanyo lweSigaba soku-1. NgoDisemba ka-2023, iVerastem ikhethe i-GFH375/VS-7375, i-KRAS G12D (ON/OFF) inhibitor yomlomo, njengenkqubo yayo ephambili kwintsebenziswano, kwaye ilayisenisi ye-GFH375 eyasetyenziswa ngoJanuwari ka-2025 yayiyeyokuqala kule ntsebenziswano. Iilayisenisi zinika iVerastem amalungelo ophuhliso kunye norhwebo ngaphandle kweTshayina, ngelixa iGenFleet igcina amalungelo ngaphakathi kweTshayina.
**Idatha yovavanyo lweklinikhi oluthembisayo lweSigaba soku-1/sesi-2 evezwe kwiNgqungquthela ye-ESMO ka-2025:**
- 91.5% yezigulane ziye zancipha kwizilonda ekujoliswe kuzo
- Izinga lokuphendula ngokwenjongo (ORR) lifikelele kwi-40.7%
Izinga lokulawula izifo (DCR) beliphezulu ukuya kuthi ga kwi-96.7%
- Ukusinda okungenankqubela phambili okuphakathi (mPFS) bekuziinyanga ezi-5.52
- Izinga lokusinda elingenankqubela-phambili leenyanga ezi-4 yayiyi-78.2%
Olu lwazi, olufunyenwe kwizigulana ezingama-59 ezine-KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC) eziye zafumana unyango lwenkqubo yangaphambili, lubonisa ngokucacileyo umsebenzi onamandla wokulwa nethumba we-GFH375 kumhlaza wepancreatic ongenakuthintelwa.
**Kutheni Ukhetha iSebe leMicimbi yeHlabathi leSibhedlele se-Oncology saseBeijing South Region?**
Njengovulindlela kwiinkonzo zonyango zamazwe ngamazwe, iSebe leeNgcali zeSibhedlele se-Oncology saseBeijing South Region International lizimisele ukubonelela izigulane zehlabathi ngezi zinto zilandelayo:
- Iinkonzo zokubonisana ngezonyango zobungcali kunye neenkonzo zokuqeshwa ngeenjongo ezahlukeneyo
- Ukufikelela kwiingcali eziphambili ze-oncology eTshayina nakwamanye amazwe
- Itshaneli eluhlaza enye yokumisa unyango oluwela imida
Siyaqonda ukuba kwizigulane ezinomhlaza oqhubele phambili, yonke imihla yokulinda izisa umngcipheko omkhulu. Ke ngoko, simisele iindlela ezininzi zonxibelelwano zamazwe ngamazwe ezifanelekileyo ukuqinisekisa ukuba ufumana inkxaso yobungcali ngexesha elifanelekileyo.
**Nxibelelana nathi namhlanje uze uqale uhambo lwakho lwethemba**
��� Inombolo yomnxeba: 400-880-3716
��� I-WeChat: 17801183037
��� I-imeyile:
- 100085_010@163.com
- myimmnet@163.com
Kungakhathaliseki ukuba ukuliphi ilizwe okanye ummandla, okanye ukuba zingaphi iindlela zonyango osele uzizamile, iSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region International likulungele ukuma nawe ekulweni kwakho nomhlaza. Inkqubela phambili ye-GFH375 isenokuba lukhanyiso obululindele.
Call 400-880-3716, add us on WeChat at 17801183037, or email us at 100085_010@163.com or myimmnet@163.com.
Sisonke, masilwele amathuba amaninzi obomi.
> Qaphela: I-GFH375 ayikavunywa ngokusemthethweni ukuba ithengiswe kwilizwekazi laseTshayina. Ukuchonga kwayo i-Breakthrough Therapy kulindeleke ukuba kukhawulezise ukufikeleleka kwezonyango. ISebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region liza kujonga ngokusondeleyo inkqubela phambili ekufikeleleni kwiziyobisi kwaye libonelele ngolwazi malunga nonyango oluphambili kunye neenkonzo zokulungelelanisa izigulane ezifanelekileyo. Nceda ulandele isikhokelo sikagqirha wakho malunga nezicwangciso zonyango ezithile.
Ixesha lokuthumela: Epreli-10-2026